Article

Peripheral Artery Disease Hotspots around the US

Detroit boasts the highest rate of PAD among its population of any US city, making it the number-one PAD "Hot Spot" in the country.

As part of peripheral artery disease (PAD) awareness month, the National Minority Quality Forum based on data on PAD compiled from the 2005 Behavioral Risk Factor Surveillance System and age, gender, ethnicity, and other demographic data from the 2000 US Census—has revealed that Detroit boasts the highest rate of PAD among its population of any US city, making it the number-one PAD “Hot Spot” in the country.

The complete list of PAD Hot Spots can be accessed at the P.A.D: Make the Connection website, an educational resource sponsored by Bristol-Myers Squibb and sanofi-aventis in partnership with the P.A.D. Coalition. Rounding out the top 10 Hot Spots on the list are Washington, DC, Baltimore, Philadelphia, Cleveland, St. Louis, Memphis, Buffalo, Pittsburgh, and Atlanta.

Patients and physicians can visit the P.A.D: Make the Connection website to access additional information about PAD, including how the condition develops, the symptoms that may indicate a patient has PAD, risk factors associated with PAD, and how the Ankle-Brachial Index and others tests can be used to diagnose PAD.

Visitors to the site can sign up to receive a free information kit that includes a doctor discussion guide and a risk assessor.

Additional PAD Resources

Find a PAD screening site

The “Legs for Life” campaign screening directory

Society for Vascular Surgery screening resources

Info on the Ankle-Brachial Index

PAD facts and information from the American Heart Association

American Academy of Family Physicians management recommendations for PAD

Related Videos
Brigit Vogel, MD: Exploring Geographical Disparities in PAD Care Across US| Image Credit: LinkedIn
| Image Credit: X
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Stephen Nicholls, MBBS, PhD | Credit: Monash University
Marianna Fontana, MD, PhD: Nex-Z Shows Promise in ATTR-CM Phase 1 Trial | Image Credit: Radcliffe Cardiology
Zerlasiran Achieves Durable Lp(a) Reductions at 60 Weeks, with Stephen J. Nicholls, MD, PhD | Image Credit: Monash University
Muthiah Vaduganathan, MD, MPH | Credit: Brigham and Women's Hospital
Viet Le, DMSc, PA-C | Credit: APAC
Marianna Fontana, MD, PhD: Declines in Kidney Function Frequent in ATTR-CM  | Image Credit: Radcliffe Cardiology
© 2024 MJH Life Sciences

All rights reserved.